gmp
gmp

Find Clinical Drug Pipeline Developments & Deals by Lannett Company, Inc.

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Fluticasone

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Flovent Diskus

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Respirent Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement August 17, 2020

            Details:

            Lannett announced that it has entered into an exclusive U.S. distribution agreement for the therapeutically equivalent generic of Flovent® Diskus® (Fluticasone Propionate Powder Inhaler) of Respirent Pharmaceuticals.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mexiletine

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: RIVOPHARM SA

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration July 23, 2020

            Details:

            Under the agreement, Lannett will primarily provide sales, marketing and distribution support for the product, for which it will receive a percentage of net profits. Other financial terms were not disclosed.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Levothyroxine Sodium

            Therapeutic Area: Endocrinology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Cediprof

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement July 16, 2020

            Details:

            The companies have entered into an interim exclusive supply and distribution agreement for Cediprof's FDA approved Levothyroxine Sodium Tablets USP. Lannett to Commence Marketing on August 3, 2020.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Glargine

            Therapeutic Area: Endocrinology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 11, 2020

            Details:

            At the Biosimilar Biological Product Development Type II meeting the FDA provided positive feedback on the clinical and Chemistry, Manufacturing and Controls advancement of company's biosimilar insulin glargine that was consistent with our expectations.